Select Topic:
Browse by Series:

Impact of the PACIFIC Study Updated Analysis

Insights From: Nicolas Girard, MD, Curie Institute
Published: Tuesday, May 14, 2019



Transcript:

Nicolas Girard, MD:
In the updated analysis of PACIFIC, we now have a clear view of the progression pattern during durvalumab consolidation. The first point is that we have a reduction in the risk of disease progression, and this is related to a reduction in the risk of distant metastasis. Meaning that we have a decrease in the incidence of brain metastasis and lung metastasis, and we have a global effect of durvalumab on this time to distant metastasis. And this is what we have actually in the clinic. We know that after chemoradiation, we have a higher risk of recurrence in the brain, in the lung, in the liver
Slider Left
Slider Right


Transcript:

Nicolas Girard, MD:
In the updated analysis of PACIFIC, we now have a clear view of the progression pattern during durvalumab consolidation. The first point is that we have a reduction in the risk of disease progression, and this is related to a reduction in the risk of distant metastasis. Meaning that we have a decrease in the incidence of brain metastasis and lung metastasis, and we have a global effect of durvalumab on this time to distant metastasis. And this is what we have actually in the clinic. We know that after chemoradiation, we have a higher risk of recurrence in the brain, in the lung, in the liver
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x